TY - JOUR
T1 - Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe
AU - Michelsen, Brigitte
AU - Østergaard, Mikkel
AU - Nissen, Michael John
AU - Ciurea, Adrian
AU - Möller, Burkhard
AU - Ørnbjerg, Lykke Midtbøll
AU - Zavada, Jakub
AU - Glintborg, Bente
AU - MacDonald, Alan
AU - Laas, Karin
AU - Nordström, Dan
AU - Gudbjornsson, Bjorn
AU - Iannone, Florenzo
AU - Hellmand, Pasoon
AU - Kvien, Tore Kristian
AU - Rodrigues, Ana Maria
AU - Codreanu, Catalin
AU - Rotar, Ziga
AU - Castrejón Fernández, Isabel
AU - Wallman, Johan Karlsson
AU - Vencovsky, Jiri
AU - Loft, Anne Gitte
AU - Heddle, Maureen
AU - Vorobjov, Sigrid
AU - Hokkanen, Anna Mari
AU - Gröndal, Gerdur
AU - Sebastiani, Marco
AU - van de Sande, Marleen
AU - Kristianslund, Eirik Klami
AU - Santos, Maria José
AU - Mogosan, Corina
AU - Tomsic, Matija
AU - Díaz-González, Federico
AU - Di Giuseppe, Daniela
AU - Hetland, Merete Lund
N1 - Publisher Copyright:
© 2023 The Author(s)
PY - 2023
Y1 - 2023
N2 - This is the first report comparing EULAR and national treatment recommendations for PsA patients across Europe, and the first this decade to compare ASAS-EULAR and national treatment recommendations in axSpA patients. An electronic survey was completed from October 2021–April 2022 by rheumatologists in 15 European countries. One and four countries followed all EULAR and ASAS-EULAR recommendations, respectively. Five countries had no national treatment recommendations for PsA and/or axSpA, but followed other regulations. In several countries, national treatment recommendations predated the most recent EULAR/ASAS-EULAR recommendations. Entry criteria for starting biologic/targeted synthetic disease-modifying anti-rheumatic drugs varied considerably. In several countries, for PsA patients with significant skin involvement, interleukin-17 inhibitors were not given preference. The positioning of Janus Kinase inhibitors differed and Phosphodiesterase-4 inhibitors were not in use/reimbursed in most countries. This study may motivate European countries to update their national treatment recommendations, to align them better with the latest international recommendations.
AB - This is the first report comparing EULAR and national treatment recommendations for PsA patients across Europe, and the first this decade to compare ASAS-EULAR and national treatment recommendations in axSpA patients. An electronic survey was completed from October 2021–April 2022 by rheumatologists in 15 European countries. One and four countries followed all EULAR and ASAS-EULAR recommendations, respectively. Five countries had no national treatment recommendations for PsA and/or axSpA, but followed other regulations. In several countries, national treatment recommendations predated the most recent EULAR/ASAS-EULAR recommendations. Entry criteria for starting biologic/targeted synthetic disease-modifying anti-rheumatic drugs varied considerably. In several countries, for PsA patients with significant skin involvement, interleukin-17 inhibitors were not given preference. The positioning of Janus Kinase inhibitors differed and Phosphodiesterase-4 inhibitors were not in use/reimbursed in most countries. This study may motivate European countries to update their national treatment recommendations, to align them better with the latest international recommendations.
KW - Axial spondyloarthritis
KW - Health policy
KW - Psoriatic arthritis
KW - Treatment recommendations
U2 - 10.1016/j.lanepe.2023.100706
DO - 10.1016/j.lanepe.2023.100706
M3 - Review
C2 - 37601339
AN - SCOPUS:85166759844
VL - 33
JO - The Lancet Regional Health - Europe
JF - The Lancet Regional Health - Europe
SN - 2666-7762
M1 - 100706
ER -